RhumbLine Advisers’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.5M | Sell |
85,916
-5,810
| -6% | -$1.03M | 0.01% | 769 |
|
|
2026
Q1 | $15.8M | Buy |
91,726
+3,217
| +4% | +$596K | 0.01% | 832 |
|
|
2025
Q4 | $17.7M | Sell |
88,509
-8,060
| -8% | -$1.46M | 0.01% | 770 |
|
|
2025
Q3 | $15.1M | Buy |
96,569
+1,427
| +1% | +$227K | 0.01% | 889 |
|
|
2025
Q2 | $14.4M | Buy |
95,142
+8,412
| +10% | +$1.12M | 0.01% | 890 |
|
|
2025
Q1 | $13.1M | Buy |
86,730
+3,405
| +4% | +$571K | 0.01% | 902 |
|
|
2024
Q4 | $15.4M | Sell |
83,325
-3,009
| -3% | -$580K | 0.01% | 838 |
|
|
2024
Q3 | $17M | Sell |
86,334
-1,952
| -2% | -$406K | 0.02% | 794 |
|
|
2024
Q2 | $18.2M | Buy |
88,286
+1,245
| +1% | +$282K | 0.02% | 721 |
|
|
2024
Q1 | $23.6M | Sell |
87,041
-81
| -0.1% | -$19.3K | 0.02% | 612 |
|
|
2023
Q4 | $20.6M | Buy |
87,122
+1,875
| +2% | +$369K | 0.02% | 671 |
|
|
2023
Q3 | $16.7M | Sell |
85,247
-133
| -0.2% | -$27.3K | 0.02% | 722 |
|
|
2023
Q2 | $18M | Sell |
85,380
-7,489
| -8% | -$1.49M | 0.02% | 707 |
|
|
2023
Q1 | $18.7M | Buy |
92,869
+6,833
| +8% | +$1.55M | 0.02% | 638 |
|
|
2022
Q4 | $18.7M | Buy |
86,036
+2,715
| +3% | +$593K | 0.03% | 617 |
|
|
2022
Q3 | $16.4M | Buy |
83,321
+624
| +0.8% | +$135K | 0.02% | 623 |
|
|
2022
Q2 | $17.7M | Buy |
82,697
+9,214
| +13% | +$2.25M | 0.03% | 603 |
|
|
2022
Q1 | $20.9M | Sell |
73,483
-12,085
| -14% | -$3.73M | 0.03% | 555 |
|
|
2021
Q4 | $32.2M | Buy |
85,568
+4,337
| +5% | +$1.68M | 0.04% | 403 |
|
|
2021
Q3 | $33.5M | Sell |
81,231
-3,468
| -4% | -$1.44M | 0.05% | 364 |
|
|
2021
Q2 | $31.3M | Sell |
84,699
-50,319
| -37% | -$16.8M | 0.04% | 400 |
|
|
2021
Q1 | $39.1M | Sell |
135,018
-2,843
| -2% | -$790K | 0.05% | 309 |
|
|
2020
Q4 | $34.4M | Sell |
137,861
-4,179
| -3% | -$995K | 0.05% | 346 |
|
|
2020
Q3 | $32.2M | Sell |
142,040
-5,138
| -3% | -$1.07M | 0.05% | 327 |
|
|
2020
Q2 | $25.7M | Buy |
147,178
+12,432
| +9% | +$1.98M | 0.04% | 382 |
|
|
2020
Q1 | $17M | Sell |
134,746
-3,261
| -2% | -$489K | 0.04% | 437 |
|
|
2019
Q4 | $21.1M | Buy |
138,007
+3,104
| +2% | +$430K | 0.04% | 466 |
|
|
2019
Q3 | $17.9M | Sell |
134,903
-1,486
| -1% | -$199K | 0.03% | 489 |
|
|
2019
Q2 | $19.4M | Buy |
136,389
+1,465
| +1% | +$199K | 0.04% | 461 |
|
|
2019
Q1 | $19.6M | Sell |
134,924
-1,795
| -1% | -$236K | 0.04% | 442 |
|
|
2018
Q4 | $15.5M | Buy |
136,719
+33,334
| +32% | +$4.17M | 0.03% | 520 |
|
|
2018
Q3 | $13.9M | Sell |
103,385
-3,578
| -3% | -$442K | 0.03% | 549 |
|
|
2018
Q2 | $12M | Buy |
106,963
+4,842
| +5% | +$523K | 0.02% | 597 |
|
|
2018
Q1 | $10.9M | Sell |
102,121
-5,892
| -5% | -$635K | 0.02% | 634 |
|
|
2017
Q4 | $11.8M | Buy |
108,013
+3,201
| +3% | +$348K | 0.02% | 612 |
|
|
2017
Q3 | $11.3M | Buy |
104,812
+5,574
| +6% | +$573K | 0.02% | 614 |
|
|
2017
Q2 | $10M | Sell |
99,238
-423
| -0.4% | -$38.9K | 0.02% | 634 |
|
|
2017
Q1 | $8.96M | Buy |
99,661
+3,150
| +3% | +$268K | 0.02% | 697 |
|
|
2016
Q4 | $7.35M | Buy |
96,511
+4,957
| +5% | +$376K | 0.02% | 761 |
|
|
2016
Q3 | $7.63M | Buy |
91,554
+2,104
| +2% | +$176K | 0.02% | 679 |
|
|
2016
Q2 | $7.37M | Buy |
89,450
+2,689
| +3% | +$221K | 0.02% | 657 |
|
|
2016
Q1 | $6.59M | Buy |
86,761
+116
| +0.1% | +$8.59K | 0.02% | 706 |
|
|
2015
Q4 | $6.96M | Buy |
86,645
+477
| +0.6% | +$34.4K | 0.02% | 667 |
|
|
2015
Q3 | $5.47M | Buy |
86,168
+3,442
| +4% | +$247K | 0.02% | 766 |
|
|
2015
Q2 | $5.82M | Buy |
82,726
+2,091
| +3% | +$155K | 0.02% | 761 |
|
|
2015
Q1 | $6.39M | Buy |
80,635
+4,820
| +6% | +$356K | 0.02% | 716 |
|
|
2014
Q4 | $4.83M | Buy |
75,815
+745
| +1% | +$46.7K | 0.01% | 819 |
|
|
2014
Q3 | $4.49M | Buy |
75,070
+977
| +1% | +$55.9K | 0.01% | 827 |
|
|
2014
Q2 | $3.96M | Sell |
74,093
-6,774
| -8% | -$372K | 0.01% | 923 |
|
|
2014
Q1 | $4.88M | Sell |
80,867
-139
| -0.2% | -$8.1K | 0.01% | 832 |
|
|
2013
Q4 | $4.3M | Sell |
81,006
-4,793
| -6% | -$241K | 0.01% | 903 |
|
|
2013
Q3 | $3.97M | Buy |
85,799
+590
| +0.7% | +$27.1K | 0.01% | 925 |
|
|
2013
Q2 | $3.5M | Buy |
+85,209
| New | +$3.65M | 0.01% | 963 |
|
Other funds holding CRL
AI
RhumbLine Advisers's CRL Position: Q2 2026 in Review
RhumbLine Advisers reduced its Charles River Laboratories (CRL) stake by 6.3% in Q2 2026, selling an estimated $1.03M and leaving 85,916 shares worth $19.5M. The position accounts for 0.01% of the portfolio, ranked #769.
RhumbLine Advisers first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $39.1M in Q1 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- RhumbLine Advisers held 85,916 shares of Charles River Laboratories worth $19.5M as of Q2 2026.
- RhumbLine Advisers sold 5,810 Charles River Laboratories shares in Q2 2026, an estimated $1.03M.
- Charles River Laboratories made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #769 holding.
- RhumbLine Advisers first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Charles River Laboratories position peaked at $39.1M in Q1 2021.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.